Skip to main content

Educating Your Patients About Daratumumab

Hematologic Cancers, Conference Correspondent, ASH Highlights
Conference Correspondent 
Leslie Lauersdorf insist that it's vital to inform your patients about what's involved in beginning daratumumab treatments, especially because of the lengthy chair time.

Related Items

Polatuzumab Vedotin plus R-CHP Outperforms Standard of Care in Treatment of DLBCL
TOP - March 2022 Vol 15, No 2
ASH Highlights, Lymphoma
Time-Limited Venetoclax-Based Regimens Demonstrate Promising Efficacy in Fit Patients with CLL
TOP - March 2022 Vol 15, No 2
ASH Highlights
Mosunetuzumab Induces Deep Remissions in Patients with Relapsed/Refractory Follicular Lymphoma
By William King
TOP - January 2022 Vol 15, No 1 – Online Only
ASH Highlights
Results from 2 Studies Provide Insights on Antibody Response to COVID-19 Vaccines in Patients with Hematologic Malignancies
By William King
TOP - January 2022 Vol 15, No 1 – Online Only
ASH Highlights